Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida

1 N.M.J. van der Put, MSc, F.J.M. Trijbels, PhD (Prof), L.P. van den Heuvel, PhD, H.J. Blom, PhD,
2 R.P.M. Steegers-Theunissen, MD, T.K.A.B. Eskes, MD, E.C.M. Mariman, PhD, M. den Heyer,
3 M.D., P. Frosst, MSc, R. Rozen, PhD

Department of Pediatrics, University Hospital Nijmegen, United Kingdom
Department of Obstetrics and Gynecology, University Hospital Nijmegen, United Kingdom
Department of Epidemiology, University Hospital Nijmegen, United Kingdom
Department of Human Genetics, University Hospital Nijmegen, United Kingdom
Department of Hematology, Municipal Hospital Leyenburg, The Hague, Netherlands
Departments of Human Genetics, Pediatrics, and Biology, McGill University, Montreal, Canada

Abstract

Periconceptional folate supplementation reduces the risk of neural-tube defects. We studied the frequency of the 677C→T mutation in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene in 55 patients with spina bifida and parents of such patients (70 mothers, 60 fathers), 5% of 207 controls were homozygous for the 677C→T mutation compared with 16% of mothers, 10% of fathers, and 13% of patients. The mutation was associated with decreased MTHFR activity, low plasma folate, and high plasma homocysteine and red-cell folate concentrations. The 677C→T mutation should be regarded as a genetic risk factor for spina bifida.